Recent Patents on Biomarkers (Discontinued) - Volume 3, Issue 2, 2013

Cardiac disease is a leading cause of morbidity and mortality worldwide and is likely to remain a major challenge into the 21st century because of population aging and global epidemic of obesity. Primary prevention is the most effective way to reduce the disease burden but has produced limited success due to challenges in its societal implementation and individual compliance. The alternative, complementary approach co Read More

Nervous system tumors include a wide variety of entities, classified according to histopathological features or their location within the CNS. The high grade gliomas - anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) – have a very poor prognosis and, despite intensive conventional therapy, the median survival rate for patients with GBM is approximately 1 year. Investigation on molecular level of glioblas Read More

In spite of recent advances in colon cancer treatment, patients with advanced disease have a poor prognosis. Thus, early diagnosis of the disease, associated with development of new therapeutic strategies, is essential to improve the survival of these patients. In this context, the identification of new biomarkers that can help detect, classify and define the prognosis of patients with colon cancer is of great interest. To date, ther Read More

Throughout the scientific community, early detection is considered as the best form of cancer prevention. However, there has been a lack of suitable and reliable early detection markers. For example, CA-125 has been at the forefront of monitoring and treatment of ovarian cancer but it is a poor biomarker with a sensitivity level of 40%, indicating that the need for more promising early detection methods is imperative. Rec Read More

In the recent years, a large number of potential biomarkers for asthma and Chronic Obstructive Pulmonary Disease (COPD) have been described. Biomarkers derive from a variety of sources (bronchioalveolar lavage fluid, sputum, exhaled breath, and blood), provide complementary information to ascertain disease diagnosis, stage, activity/progression and/or treatment responses. The present review highlights the cur Read More

The aim of the study was to verify the usefulness of biomarkers in lung cancer. Thus, serum levels of tumor markers, including Pro-gastrin-releasing peptide (ProGRP), Neuron-specific enolase (NSE) and Cyfra 21-1 were evaluated competitively in benign and malignant lung diseases. Serum samples of 469 consecutive patients were investigated in two different groups. Group 1(NSE, ProGRP) contained 90 cases of benign lung Read More